Merck & Co., Inc. MRK NYSE

Merck & Co., Inc. (MRK) generated $16.47B in operating cash flow for fiscal year 2025. After capital expenditures of $4.11B, free cash flow was $12.36B.

Free cash flow margin was 19% of revenue. Cash conversion ratio was 0.9x, suggesting some earnings are non-cash.

The company returned $8.18B in dividends and $5.08B in share buybacks to shareholders during the period.

Criteria supported by this page:

• HEALTH (83/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (94/100, Pass) — $12.36B (19% FCF margin) supports a durable competitive advantage
• INCOME (85/100) — Cash conversion ratio was 0.9x suggests some earnings are non-cash items

Overall SharesGrow Score: 83/100 with 7/7 criteria passed.